# NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

> **NCT04615013** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Cervical Esophagus Adenocarcinoma
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage II Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
- Thoracic Esophagus Adenocarcinoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Fluorouracil
- **OTHER:** Hafnium Oxide-containing Nanoparticles NBTXR3
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04615013
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-23
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04615013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04615013, "NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04615013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*